Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna
The Lancet Regional Health Western Pacific
; 30:100634, 2023.
Article
in English
| MEDLINE | ID: covidwho-2131792
ABSTRACT
Background:
Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low immunity and high levels of comorbidities, we investigate how targeted use of nirmatrelvir/ritonavir (brand name Paxlovid) can complement vaccination and non-pharmaceutical interventions (NPIs), and mitigate the epidemic rebound expected when Zero-COVID ends.
Full text:
Available
Collection:
Databases of international organizations
Database:
MEDLINE
Topics:
Vaccines
Language:
English
Journal:
The Lancet Regional Health Western Pacific
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS